A Phase III, Open-label Study of Once Daily BI 201335 240 mg for 24 Weeks in Combination With Pegylated interferon-a (PegIFN) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN / RBV Treatment

Trial Profile

A Phase III, Open-label Study of Once Daily BI 201335 240 mg for 24 Weeks in Combination With Pegylated interferon-a (PegIFN) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Failed a Prior PegIFN / RBV Treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Faldaprevir (Primary) ; Peginterferon alfa; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 09 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 25 Jun 2014 Planned End Date changed from 1 Oct 2014 to 1 Jun 2014 as reported by CllinicalTrials.gov record.
    • 05 Mar 2014 Planned end date changed from 1 Sep 2015 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top